FCF Yield

With a Free Cash Flow (FCF) Yield of -10.1%, Beam Therapeutics is consuming more cash than it generates — a negative yield means the company’s market value exceeds the cash it produces, often typical for growth-stage biotechs.

This places Beam in the 16th percentile among healthcare sector peers, far below the sector median of 3.6%, indicating weaker cash generation relative to nearly all competitors. Year-over-year change is not available, but quarter-over-quarter the FCF Yield improved by 22.9% (from -13.1% to -10.1%), showing a narrowing cash burn rate. The combination of a deeply negative yield with a recent quarterly improvement suggests high cash-consumption risk remains, though the trend toward less negative territory reduces immediate liquidity pressure. This mixed picture aligns with the overall NEUTRAL verdict — the poor absolute level signals caution, while the improving quarterly trend offers a counterbalance, neither confirming a clear buy nor sell case.

Frequently Asked Questions

Closest Sector Peers